Cargando…
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
INTRODUCTION: Using data from the ertugliflozin cardiovascular outcomes trial in patients with type 2 diabetes mellitus (VERTIS CV; NCT01986881), associations between the initial estimated glomerular filtration rate (eGFR) “dip” with eGFR slope, glucosuria/natriuresis-related measures, and safety we...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501765/ https://www.ncbi.nlm.nih.gov/pubmed/35691283 http://dx.doi.org/10.1159/000524889 |
_version_ | 1784795550458052608 |
---|---|
author | Cherney, David Z.I. Cosentino, Francesco Dagogo-Jack, Samuel McGuire, Darren K. Pratley, Richard E. Frederich, Robert Maldonado, Mario Liu, Chih-Chin Pong, Annpey Cannon, Christopher P. |
author_facet | Cherney, David Z.I. Cosentino, Francesco Dagogo-Jack, Samuel McGuire, Darren K. Pratley, Richard E. Frederich, Robert Maldonado, Mario Liu, Chih-Chin Pong, Annpey Cannon, Christopher P. |
author_sort | Cherney, David Z.I. |
collection | PubMed |
description | INTRODUCTION: Using data from the ertugliflozin cardiovascular outcomes trial in patients with type 2 diabetes mellitus (VERTIS CV; NCT01986881), associations between the initial estimated glomerular filtration rate (eGFR) “dip” with eGFR slope, glucosuria/natriuresis-related measures, and safety were investigated. METHODS: Patients were categorized into tertiles based on change in eGFR at week 6: >+1.00 mL/min/1.73 m<sup>2</sup> (tertile 1), >−5.99 and ≤+1.00 (tertile 2), and ≤−6.00 (tertile 3). eGFR slope after week 6 and week 18 was assessed by tertile. Glucosuria/natriuresis-related measures were also determined. Adverse events (AEs) were analyzed in the acute (baseline–week 6) and chronic periods (week 6–30 days after last dose of trial medication). RESULTS: In the ertugliflozin group, chronic eGFR slopes (95% CI, mL/min/1.73 m<sup>2</sup>/year; weeks 6–156) were −0.76 (−1.03, −0.50), −0.29 (−0.51, −0.07), and −0.05 (−0.26, 0.17) in tertiles 1, 2, and 3, respectively (p value <0.001), and approximately −1.5 mL/min/1.73 m<sup>2</sup>/year across tertiles in the placebo group (p value = 0.79). At week 18, least squares mean (LSM) changes from baseline in glycated hemoglobin (%) were −0.77, −0.71, and −0.67 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; a similar tertile-associated trend was observed for uric acid. At week 18, LSM changes from baseline in hematocrit (%) were 2.07, 2.33, and 2.55 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; similar tertile-associated trends were observed for blood pressure. All p<sub>interaction</sub> values were <0.0001 for glucosuria- and natriuresis-related measures. Kidney-related AEs were reported more frequently in tertiles 3 and 2 in the chronic period for both placebo- and ertugliflozin-treated groups. In both periods and in all tertiles, incidences of AEs did not differ between placebo- and ertugliflozin-treated groups. CONCLUSION: With ertugliflozin, the tertile with the largest initial dip in eGFR had a slower rate of chronic eGFR decline. Initial eGFR changes were associated with changes in both glucosuria- and natriuresis-related measures. |
format | Online Article Text |
id | pubmed-9501765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-95017652022-09-24 Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial Cherney, David Z.I. Cosentino, Francesco Dagogo-Jack, Samuel McGuire, Darren K. Pratley, Richard E. Frederich, Robert Maldonado, Mario Liu, Chih-Chin Pong, Annpey Cannon, Christopher P. Am J Nephrol Patient-Oriented, Translational Research: Research Article INTRODUCTION: Using data from the ertugliflozin cardiovascular outcomes trial in patients with type 2 diabetes mellitus (VERTIS CV; NCT01986881), associations between the initial estimated glomerular filtration rate (eGFR) “dip” with eGFR slope, glucosuria/natriuresis-related measures, and safety were investigated. METHODS: Patients were categorized into tertiles based on change in eGFR at week 6: >+1.00 mL/min/1.73 m<sup>2</sup> (tertile 1), >−5.99 and ≤+1.00 (tertile 2), and ≤−6.00 (tertile 3). eGFR slope after week 6 and week 18 was assessed by tertile. Glucosuria/natriuresis-related measures were also determined. Adverse events (AEs) were analyzed in the acute (baseline–week 6) and chronic periods (week 6–30 days after last dose of trial medication). RESULTS: In the ertugliflozin group, chronic eGFR slopes (95% CI, mL/min/1.73 m<sup>2</sup>/year; weeks 6–156) were −0.76 (−1.03, −0.50), −0.29 (−0.51, −0.07), and −0.05 (−0.26, 0.17) in tertiles 1, 2, and 3, respectively (p value <0.001), and approximately −1.5 mL/min/1.73 m<sup>2</sup>/year across tertiles in the placebo group (p value = 0.79). At week 18, least squares mean (LSM) changes from baseline in glycated hemoglobin (%) were −0.77, −0.71, and −0.67 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; a similar tertile-associated trend was observed for uric acid. At week 18, LSM changes from baseline in hematocrit (%) were 2.07, 2.33, and 2.55 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; similar tertile-associated trends were observed for blood pressure. All p<sub>interaction</sub> values were <0.0001 for glucosuria- and natriuresis-related measures. Kidney-related AEs were reported more frequently in tertiles 3 and 2 in the chronic period for both placebo- and ertugliflozin-treated groups. In both periods and in all tertiles, incidences of AEs did not differ between placebo- and ertugliflozin-treated groups. CONCLUSION: With ertugliflozin, the tertile with the largest initial dip in eGFR had a slower rate of chronic eGFR decline. Initial eGFR changes were associated with changes in both glucosuria- and natriuresis-related measures. S. Karger AG 2022-08 2022-06-10 /pmc/articles/PMC9501765/ /pubmed/35691283 http://dx.doi.org/10.1159/000524889 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Patient-Oriented, Translational Research: Research Article Cherney, David Z.I. Cosentino, Francesco Dagogo-Jack, Samuel McGuire, Darren K. Pratley, Richard E. Frederich, Robert Maldonado, Mario Liu, Chih-Chin Pong, Annpey Cannon, Christopher P. Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title_full | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title_fullStr | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title_full_unstemmed | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title_short | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial |
title_sort | initial egfr changes with ertugliflozin and associations with clinical parameters: analyses from the vertis cv trial |
topic | Patient-Oriented, Translational Research: Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501765/ https://www.ncbi.nlm.nih.gov/pubmed/35691283 http://dx.doi.org/10.1159/000524889 |
work_keys_str_mv | AT cherneydavidzi initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT cosentinofrancesco initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT dagogojacksamuel initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT mcguiredarrenk initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT pratleyricharde initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT frederichrobert initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT maldonadomario initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT liuchihchin initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT pongannpey initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial AT cannonchristopherp initialegfrchangeswithertugliflozinandassociationswithclinicalparametersanalysesfromthevertiscvtrial |